

Daniel Vilarim Araújo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5752286/publications.pdf>

Version: 2024-02-01

24
papers

490
citations

1040056

9
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

602
citing authors

#	ARTICLE	IF	CITATIONS
1	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. <i>Cancers</i> , 2022, 14, 89.	3.7	5
2	When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. <i>Targeted Oncology</i> , 2022, 17, 253-270.	3.6	5
3	Early circulating tumor DNA (ctDNA) kinetics using a tumor-naïve assay as a predictive biomarker in early-phase immunotherapy (IO) clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2546.	1.6	13
4	Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9579-9579.	1.6	5
5	Is there a role for surgery after chemotherapy in recurrent/metastatic adrenal cortical cancer (ACC)?. <i>Journal of Clinical Oncology</i> , 2022, 40, 5092-5092.	1.6	0
6	Adherence and perception of the importance of anti-COVID-19 protective measures amongst patients with cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24120-e24120.	1.6	1
7	Patient-centered trials in oncology: Time for a change. <i>Med</i> , 2022, 3, 445-449.	4.4	0
8	Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics. <i>Cancer Treatment Reviews</i> , 2021, 92, 102125.	7.7	15
9	The Day After COVID-19“Time to Rethink Oncology Clinical Research. <i>JAMA Oncology</i> , 2021, 7, 23.	7.1	6
10	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa122.	2.9	12
11	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	46.4	208
12	Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. <i>Current Oncology</i> , 2021, 28, 2173-2179.	2.2	14
13	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) “an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , 2021, 12, 820-826.	1.0	10
14	Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 3640.	3.7	4
15	Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil. <i>Ecancermedalscience</i> , 2021, 15, 1269.	1.1	1
16	Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor“Like Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2470-2479.	0.7	1
17	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. , 2021, 9, e003476.		20
18	Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era. <i>European Journal of Cancer</i> , 2021, 158, 85-98.	2.8	16

#	ARTICLE	IF	CITATIONS
19	Designing circulating tumor DNA-based interventional clinical trials in oncology. <i>Genome Medicine</i> , 2019, 11, 22.	8.2	24
20	Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV. <i>JAMA Network Open</i> , 2019, 2, e1914816.	5.9	11
21	The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 8.	2.5	16
22	Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model. <i>Ecancermedicalscience</i> , 2019, 13, 967.	1.1	6
23	MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2016, 139, 890-898.	5.1	45
24	Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , 2015, 137, 1397-1405.	5.1	52